1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
6Rapti I,Dimou E,Mitsoula P, et al.Adding-on versus switching to adefovir therapy in lamivudine resistant HB e antigen-negative chronic hepatitis B[J].Hepatology,2007,45(2):307-313.
7Yim HJ,Hussain M,Liu Y, et al.Evolution of multi-drug resistant hepatitis B virus during sequential therapy [J].Hepatology,2006,44 (3):703-712.
8Honkoop P,De Man RA.Entecavir:a potent new antiviral drug for hepatitis B[J].Expert Opin Investing Drugs,2003,12(4):683-688.
9Schiff E,Simsek H,Lee WM,et al.Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepaticfibrosis or cirrhosis[J].Am J Gastroenterol,2008,103(11):2776-2783.
10Chou YC,Yu MW,Wu CF,et al.Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma[J].Gut,2008,57(1):91-97.
